Achieve Life Sciences, Inc. QUIT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.93M | 41.98M | 33.26M | 31.88M | 25.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.12M | 58.28M | 52.45M | 54.88M | 52.34M |
| Operating Income | -64.12M | -58.28M | -52.45M | -54.88M | -52.34M |
| Income Before Tax | -111.71M | -114.04M | -51.99M | -54.65M | -52.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -111.71 | -114.04 | -51.99 | -54.65 | -52.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.71M | -114.04M | -51.99M | -54.65M | -52.35M |
| EBIT | -64.12M | -58.28M | -52.45M | -54.88M | -52.34M |
| EBITDA | -63.89M | -58.05M | -52.23M | -54.65M | -52.11M |
| EPS Basic | -1.38 | -1.55 | -1.12 | -1.29 | -1.38 |
| Normalized Basic EPS | -0.86 | -0.97 | -0.70 | -0.80 | -0.85 |
| EPS Diluted | -1.38 | -1.55 | -1.12 | -1.29 | -1.38 |
| Normalized Diluted EPS | -0.86 | -0.97 | -0.70 | -0.80 | -0.85 |
| Average Basic Shares Outstanding | 305.65M | 251.19M | 192.36M | 173.66M | 154.90M |
| Average Diluted Shares Outstanding | 305.65M | 251.19M | 192.36M | 173.66M | 154.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |